Key Record Dates
ClinicalTrials.gov Identifier: | NCT03861793 |
---|---|
Brief Title: | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) |
First Submitted : | February 25, 2019 |
First Submitted that Met QC Criteria : | March 1, 2019 |
First Posted : | March 4, 2019 |
Last Update Submitted that Met QC Criteria : | April 10, 2023 |
Last Update Posted : | April 11, 2023 |